Literature DB >> 3488949

Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma.

H F Sears, D Herlyn, Z Steplewski, H Koprowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3488949

Source DB:  PubMed          Journal:  Hybridoma        ISSN： 0272-457X


× No keyword cloud information.
  9 in total

1.  Remembrances of Hilary Koprowski from a Surgeon's Perspective.

Authors:  Henry F Sears
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

2.  Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.

Authors:  P Ragnhammar; G Masucci; J E Frödin; A L Hjelm; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.

Authors:  H M Blottiere; J Y Douillard; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 5.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 6.  Monoclonal antibodies in imaging and therapy of colorectal cancer.

Authors:  M K Lange; E W Martin
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

7.  Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.

Authors:  P Ragnhammar; J Fagerberg; J E Frödin; P Wersäll; L O Hansson; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1995-06       Impact factor: 6.968

8.  Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.

Authors:  Z Steplewski; L K Sun; C W Shearman; J Ghrayeb; P Daddona; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  A monoclonal antibody, KM10 reactive with human gastrointestinal cancer and its application for immunotherapy.

Authors:  H Ohyanagi; H Ishida; T Ishida; N Soyama; M Yamamoto; S Okumura; Y Kano; Y Ueda; Y Saitoh
Journal:  Jpn J Cancer Res       Date:  1988-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.